6.
Willemsen R, Weijtens M, Ronteltap C, Eshhar Z, Gratama J, Chames P
. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 2000; 7(16):1369-77.
DOI: 10.1038/sj.gt.3301253.
View
7.
Coffin J
. Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. J Gen Virol. 1979; 42(1):1-26.
DOI: 10.1099/0022-1317-42-1-1.
View
8.
Zhang J, Sapp C
. Recombination between two identical sequences within the same retroviral RNA molecule. J Virol. 1999; 73(7):5912-7.
PMC: 112652.
DOI: 10.1128/JVI.73.7.5912-5917.1999.
View
9.
Du Pasquier R, Clark K, Smith P, Joseph J, Mazullo J, De Girolami U
. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol. 2001; 7(4):318-22.
DOI: 10.1080/13550280152537175.
View
10.
Liechtenstein T, Perez-Janices N, Escors D
. Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel). 2013; 5(3):815-37.
PMC: 3785060.
DOI: 10.3390/cancers5030815.
View
11.
Joglekar A, Hollis R, Kuftinec G, Senadheera S, Chan R, Kohn D
. Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther. 2013; 21(9):1705-17.
PMC: 3776625.
DOI: 10.1038/mt.2013.106.
View
12.
Maetzig T, Galla M, Baum C, Schambach A
. Gammaretroviral vectors: biology, technology and application. Viruses. 2011; 3(6):677-713.
PMC: 3185771.
DOI: 10.3390/v3060677.
View
13.
Hoatlin M, Kozak S, Spiro C, Kabat D
. Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques. J Mol Med (Berl). 1995; 73(3):113-20.
DOI: 10.1007/BF00198238.
View
14.
Dotti G, Savoldo B, Brenner M
. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009; 20(11):1229-39.
PMC: 2829458.
DOI: 10.1089/hum.2009.142.
View
15.
Ma Q, Gonzalo-Daganzo R, Junghans R
. Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemother Biol Response Modif. 2003; 20:315-41.
View
16.
Maher J, Brentjens R, Gunset G, Riviere I, Sadelain M
. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2001; 20(1):70-5.
DOI: 10.1038/nbt0102-70.
View
17.
Yi Y, Noh M, Lee K
. Current advances in retroviral gene therapy. Curr Gene Ther. 2011; 11(3):218-28.
PMC: 3182074.
DOI: 10.2174/156652311795684740.
View
18.
Emtage P, Lo A, Gomes E, Liu D, Gonzalo-Daganzo R, Junghans R
. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res. 2008; 14(24):8112-22.
PMC: 2659496.
DOI: 10.1158/1078-0432.CCR-07-4910.
View
19.
Goedhart J, van Weeren L, Adjobo-Hermans M, Elzenaar I, Hink M, Gadella Jr T
. Quantitative co-expression of proteins at the single cell level--application to a multimeric FRET sensor. PLoS One. 2011; 6(11):e27321.
PMC: 3219669.
DOI: 10.1371/journal.pone.0027321.
View
20.
Nolan K, Yun C, Akamatsu Y, Murphy J, Leung S, Beecham E
. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res. 2000; 5(12):3928-41.
View